DPC4; JIP; MADH4; MYHRS
The SMAD4 gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518), hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400), and Myhre syndrome (MedGen UID: 167103).
Order this gene as a single gene test.
Invitae tests that include this gene:
The SMAD4 gene encodes a member of the SMAD family of signal transduction proteins. SMAD proteins are activated by transmembrane serine-threonine kinases in response to TGF-Œ≤ signaling, and inhibit cell growth and proliferation by mediating transcriptional activation of target genes.
MedGen UID: 87518
Juvenile polyposis syndrome (JPS) is a cancer predisposition syndrome that is characterized by the development of numerous hamartomatous polyps in the gastrointestinal tract (stomach, small intestine, colon, and rectum). The number of polyps varies from fewer than five to more than 100. Polyposis typically begins in the mid-teens to late twenties, but can also present in childhood. Individuals with JPS develop polyps at a young age and are most often benign, however, the term “juvenile polyp” refers to a specific histologic type of polyp, not the age at diagnosis (PMID: 22965402; 25394175; ASCO. Cancer.Net: Juvenile Polyposis Syndrome. Accessed February 2018; National Library of Medicine. Genetics Home Reference: Juvenile Polyposis Syndrome. Accessed February 2018). JPS is associated with a 17%-22% risk of colorectal cancer by age 35 and approaches 68% by age 60 (PMID: 20301642 25645574 17303595 16246179 ), a 21% risk of gastric cancer (PMID: 20301642 20859198 9869523 ), and a currently unspecified risk of pancreatic cancer (PMID: 92705469 ASCO. Cancer.Net: Juvenile Polyposis Syndrome. Accessed June 2015 ). There may also be an increased risk for other cancer types, but the current evidence is preliminary. Associated health complications may include rectal bleeding, abdominal pain, anemia, and obstruction.
In some cases, JPS presents in combination with hereditary hemorrhagic telangiectasia (HHT), which is a condition that can also occur as a result of pathogenic variants in the SMAD4 gene. HHT is characterized by epistaxis (nosebleeds) and arteriovenous malformations (AVM) due to abnormal blood vessel development, which may form in the lungs, liver, brain, and gastrointestinal tract (PMID: 20301642). The symptoms of HHT may present in early childhood. While the frequency of each HHT complication in individuals with a SMAD4 pathogenic variant is variable and not well-established, recent studies have found that HHT is a significant medical concern. Such individuals would benefit from surveillance for not only juvenile polyps but HHT-related complications as well (PMID: 20301642).
SMAD4 encodes a member of the Smad family of signal transduction proteins. The product of this gene forms homomeric complexes and heteromeric complexes with other activated Smad proteins, which then accumulate in the nucleus and regulate the transcription of target genes. This protein binds to DNA and is subject to complex regulation by post-translational modifications. If there is a pathogenic variant in this gene that prevents it from functioning normally, the risk of developing certain types of cancers and HHT is increased (NCBI Gene. Gene ID: 4089. Accessed February 2018).
JPS has autosomal dominant inheritance. This means that an individual with a pathogenic variant in SMAD4 has a 50% chance of passing the condition on to their offspring. Once a pathogenic mutation is detected in an individual, it is possible to identify at-risk relatives who can pursue testing for this specific familial variant. Most cases are inherited from a parent, but approximately 25% can occur spontaneously (i.e., an individual with a pathogenic variant has parents who do not have it) (PMID: 20301642 ).
To establish the extent of disease in an individual diagnosed with JPS, the following evaluations are recommended (PMID: 20301642; National Comprehensive Cancer Network. Surveillance Guidelines for JPS. Version 3.2017):
Early endoscopic polypectomy may reduce morbidity by reducing the risk for cancer, bleeding, or intestinal obstruction. In some cases, removal of all or part of the colon or stomach may be necessary to alleviate symptoms or to reduce cancer risk when a large number of polyps are present (PMID: 20301642 National Comprehensive Cancer Network. Surveillance Guidelines for JPS. Version 3.2017).
Due to the additional risk of HHT associated with pathogenic SMAD4 variants, it has been suggested that all affected individuals be evaluated for complications related to HHT (PMID: 20301642). The following surveillance guidelines for HHT have been proposed (PMID: 20301525):
Women with HHT considering pregnancy should be screened and treated for pulmonary and cerebral AVMs. Affected pregnant women with undetected and/or untreated AVMs (particularly lung AVMs) are at risk for serious complications; therefore, pulmonary AVMs discovered during pregnancy are treated during the second trimester. Iron replacement is preferred for anemia, but transfusion of packed red blood cells may be necessary for symptomatic anemia (PMID: 20301525).
An individual’s cancer risk and medical management are not determined by genetic test results alone. Overall cancer risk assessment incorporates additional factors, including personal medical history, family history, and any available genetic information that may result in a personalized plan for cancer prevention and surveillance.
Knowing if a pathogenic SMAD4 variant is present is advantageous. At-risk relatives can be identified, enabling pursuit of a diagnostic evaluation. Further, the available information regarding hereditary cancer susceptibility genes is constantly evolving and more clinically relevant data regarding SMAD4 are likely to become available in the near future. Awareness of this cancer predisposition encourages patients and their providers to inform at-risk family members, to diligently follow condition-specific screening protocols, and to be vigilant in maintaining close and regular contact with their local genetics clinic in anticipation of new information.
Referenced with permission from the NCCN Surveillance Guidelines for JPS. Version 3.2017. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed February 2018. To view the most recent and complete version of the guideline, go online to NCCN.org.
The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a statement of consensus of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Review date: February 2018
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence in the transcript listed below. In addition, analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any specific limitations in the analysis of these genes are also listed in the table below.
Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|